1267-STIL as a Key Driver of Li-Fraumeni Syndrome

Through a combination of multi-omics analysis and in vitro experiments, this study identifies STIL as a critical molecular link between Li-Fraumeni syndrome and osteosarcoma. The research reveals that STIL functions as a negative regulator of p53 stability, promoting tumor growth and maintaining cancer stemness regardless of the patient's specific TP53 mutation status. Using single-cell sequencing, the authors demonstrate how STIL reshapes the tumor microenvironment to facilitate immune evasion and bone destruction via specific signaling pathways like PTN–NCL. Experimental validation shows that while STIL supports proliferation in all models, it specifically drives metastatic potential in TP53-mutant backgrounds. Ultimately, the source positions STIL as a high-value prognostic biomarker and a potential target for precision therapies, such as WEE1 inhibitors.References:Qiao Y, Hao J, Yuan F, et al. Multi-omics analysis reveals the key role of STIL in Li-Fraumeni syndrome and osteosarcoma[J]. npj Precision Oncology, 2026, 10(1): 159.前往小宇宙评论区与主播互动